A 42-year-old previously healthy woman presented in 1990 with anemia and thrombocytopenia and a marrow exam, which showed 95% replacement with myeloblasts. She underwent induction therapy with daunorubicin, ARA-C and thioguanine per Eastern Cooperative Oncology Group protocol, P-C486. Because of the persistence of blasts on day 14 of treatment, she underwent a second induction with daunorubicin and ARA-C alone and was discharged home after count recovery.
/l and she was discharged home. Her leukopenia and anemia resolved; however, she required a total of 75 platelet transfusions, both pooled and human leukocyte antigen matched, for persistent thrombocytopenia over the next year on an almost weekly basis. Her platelet count eventually reached a normal value of 146 Â 10 9 /l in July 1993, almost 2 years after her last platelet transfusion (Figure 1 ).
She did well without evidence of relapse with her last follow-up in 1995. She presented to her primary care physician in October 2006 for evaluation of discoloration of a single toe. A complete blood count drawn at that time revealed a total white blood cell count of 15.3 Â 10 9 /l, hemoglobin of 14.6 g/dl and platelet count of 936 Â 10 9 /l. A bone marrow biopsy revealed a hypercellular (60%) marrow with full maturation and increased numbers of megakaryocytes with occasional dysplastic features. There was no increase in blasts, and conventional G-banding revealed normal cytogenetics for 20 metaphases. There was no endogenous erythroid colony growth. Peripheral blood DNA was found to be homozygous for the JAK2 V617F mutation ( Figure 2 ). Additionally, an archived sample from her original bone marrow harvest in 1990 was tested for the presence of the JAK2 V617F mutation which was found to be present, although in a much lower quantity as compared with the current specimen ( Figure 2 ). Hydroxyurea therapy was begun with normalization of the platelet count.
Delayed hematologic complications post-transplant, such as myelodysplasia or acute myeloid leukemia (AML) have been well described, whereas the development of a myeloproliferative disorder post transplant is much less common.
1 JAK2 V617F is a somatic point mutation seen in more than 90% of polycythemia vera patients and approximately 40-50% of patients with either V617F mutation using a semiquantitative allele-specific polymerase chain reaction (PCR). The DNA fragments corresponding to the V617F mutation and a control PCR are indicated. The concentrations of the primers have been adjusted to make the test more sensitive. As a result, the ratio of band intensities is not equal to the fraction of DNA with the mutation. The fraction of DNA with the mutation can be estimated by comparison with standards (data not shown). The SC (stem cell) lanes show that about 1% of the DNA has the JAK2 mutation. The ET lanes show that 450% of the DNA has the mutation which is consistent with homozygosity/hemizygosity in the peripheral blood obtained after the diagnosis of essential thrombocythemia. 2 Although low levels of the JAK2 V617F mutation have been reported in healthy individuals, the incidence of the mutation in de novo AML is quite low. [3] [4] [5] Also, the presence of JAK2 V617F in a single individual over a 15-year period during which both AML and essential thrombocythemia (ET) have been manifested has also not been described previously.
Bone Marrow
We do not know if the myeloid leukemia in the present case involved the JAK2 V617F mutation because the original leukemia bone marrow cells were not available for analysis. We postulate that in our patient, prolonged thrombocytopenia resulted in persistent elevation of thrombopoietin levels, which favored the proliferation of cells with the constitutively active JAK2 V617F already present in low amounts at the time of AML diagnosis. Alternatively, this abnormal clone may have simply expanded slowly over time, perhaps with the acquisition of additional mutations. We do not know how often and under what conditions a small clone with the JAK2 V617F mutation can expand to clinical significance. The present case may offer some insight into this rare clinical situation.
